BACKGROUND: Topoisomerase IIalpha (topoIIalpha) is an essential enzyme gene in regulating DNA structure and cell proliferation and is encoded by the TOP2A. Using cDNA microarray analysis, TOP2A has been reported to be one of the top genes overexpressed in Wilms' tumour. AIM: To evaluate the role of TopoIIalpha in Wilms' tumorigenesis and its prognostic value. METHODS: TOP2A gene copy numbers were determined using the fluorescence in situ hybridisation technique, and protein expression levels of TopoIIalpha by immunostaining in 39 samples of primary and 18 samples of metastatic Wilms' tumour. RESULTS: TOP2A gene amplification was detected only in anaplastic Wilms' tumours, and none of the Wilms' tumours showed deletion of the TOP2A gene. TopoIIalpha protein overexpression was detected in 97% of Wilms' tumours, and correlated strongly with proliferation, as measured by Ki-67 (r = 0.85). The high TopoIIalpha expression was associated with the presence of vascular invasion, prominent apoptosis, metastases and adverse clinical outcomes (p<0.05). CONCLUSIONS: Our findings suggest that TopoIIalpha overexpression in Wilms' tumours is caused by a change at the transcription level, except for anaplastic Wilms' tumours, in which gene amplification was present. High levels of TopoIIalpha protein are correlated with tumour aggressiveness. The assessment of TopoIIalpha expression in Wilms' tumour may have prognostic value.
BACKGROUND: Topoisomerase IIalpha (topoIIalpha) is an essential enzyme gene in regulating DNA structure and cell proliferation and is encoded by the TOP2A. Using cDNA microarray analysis, TOP2A has been reported to be one of the top genes overexpressed in Wilms' tumour. AIM: To evaluate the role of TopoIIalpha in Wilms' tumorigenesis and its prognostic value. METHODS:TOP2A gene copy numbers were determined using the fluorescence in situ hybridisation technique, and protein expression levels of TopoIIalpha by immunostaining in 39 samples of primary and 18 samples of metastatic Wilms' tumour. RESULTS:TOP2A gene amplification was detected only in anaplastic Wilms' tumours, and none of the Wilms' tumours showed deletion of the TOP2A gene. TopoIIalpha protein overexpression was detected in 97% of Wilms' tumours, and correlated strongly with proliferation, as measured by Ki-67 (r = 0.85). The high TopoIIalpha expression was associated with the presence of vascular invasion, prominent apoptosis, metastases and adverse clinical outcomes (p<0.05). CONCLUSIONS: Our findings suggest that TopoIIalpha overexpression in Wilms' tumours is caused by a change at the transcription level, except for anaplastic Wilms' tumours, in which gene amplification was present. High levels of TopoIIalpha protein are correlated with tumour aggressiveness. The assessment of TopoIIalpha expression in Wilms' tumour may have prognostic value.
Authors: John S Coon; Elizabeth Marcus; Shalina Gupta-Burt; Steven Seelig; Kris Jacobson; Shande Chen; Vivian Renta; Geraldo Fronda; Harvey D Preisler Journal: Clin Cancer Res Date: 2002-04 Impact factor: 12.531
Authors: Tatyana A Grushko; M Anne Blackwood; Phil L Schumm; Fitsum G Hagos; Moses O Adeyanju; Michael D Feldman; Melinda O Sanders; Barbara L Weber; Olufunmilayo I Olopade Journal: Cancer Res Date: 2002-03-01 Impact factor: 12.701
Authors: M F Tournade; C Com-Nougué; J de Kraker; R Ludwig; A Rey; J M Burgers; B Sandstedt; J Godzinski; M Carli; R Potter; J M Zucker Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: Masayuki Takahashi; Ximing J Yang; Todd T Lavery; Kyle A Furge; Bart O Williams; Maria Tretiakova; Anthony Montag; Nicholas J Vogelzang; Gian G Re; A Julian Garvin; Stefan Söderhäll; Susumu Kagawa; Debra Hazel-Martin; Agneta Nordenskjold; Bin Tean Teh Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: Maria S Tretiakova; Sarah D Bond; David Wheeler; Alejandro Contreras; Masha Kocherginsky; Todd G Kroll; Tracy K Hale Journal: Lab Invest Date: 2014-05-19 Impact factor: 5.662
Authors: Ryan M Gobble; Li-Xuan Qin; Elliott R Brill; Christina V Angeles; Stacy Ugras; Rachael B O'Connor; Nicole H Moraco; Penelope L Decarolis; Cristina Antonescu; Samuel Singer Journal: Cancer Res Date: 2011-02-18 Impact factor: 12.701
Authors: Harold N Lovvorn; Jenifer Westrup; Shaun Opperman; Scott Boyle; Genbin Shi; James Anderson; Elizabeth J Perlman; Alan O Perantoni; Marcia Wills; Mark de Caestecker Journal: Neoplasia Date: 2007-07 Impact factor: 5.715
Authors: M S Tretiakova; W Wei; H D Boyer; L F Newcomb; S Hawley; H Auman; F Vakar-Lopez; J K McKenney; L Fazli; J Simko; D A Troyer; A Hurtado-Coll; I M Thompson; P R Carroll; W J Ellis; M E Gleave; P S Nelson; D W Lin; L D True; Z Feng; J D Brooks Journal: Prostate Cancer Prostatic Dis Date: 2016-05-03 Impact factor: 5.554
Authors: Roula Albadine; Wenle Wang; Noel A Brownlee; Antoun Toubaji; Athanase Billis; Perdram Argani; Jonathan I Epstein; A Julian Garvin; Rima Cousi; Edward M Schaeffer; Christian Pavlovich; George J Netto Journal: J Urol Date: 2009-06-18 Impact factor: 7.450
Authors: Kerstin W Sinkevicius; Muriel Laine; Tamara L Lotan; Karolina Woloszyn; John H Richburg; Geoffrey L Greene Journal: Endocrinology Date: 2009-03-05 Impact factor: 4.736
Authors: Eric J Kort; Leslie Farber; Maria Tretiakova; David Petillo; Kyle A Furge; Ximing J Yang; Albert Cornelius; Bin T Teh Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701